Abstract:UNLABELLED:Our study indicates that recombinant adiponectin induced RANKL and inhibited OPG expression in human osteoblasts through the AdipoR1/p38 MAPK pathway, and these responses contributed to the adiponectin-induced osteoclasts formation in the co-culture of osteoblast and peripheral blood monocytes systems. These findings showed that adiponectin increased osteoclast formation indirectly through stimulating RANKL and inhibiting OPG production in osteoblasts. It also suggests the pharmacological nature of recombinant adiponectin that indirectly induces osteoclasts formation. INTRODUCTION:Recently, adiponectin has emerged as an element in the regulation of bone metabolism, but the mechanism remains. This study was undertaken to investigate the action of adiponectin on osteoclastogenesis through revealing RANKL and osteoprotegerin (OPG) expression in osteoblasts and osteoclast formation. MATERIALS AND METHODS:Real-time quantitative PCR and ELISA were used to detect RANKL and OPG mRNA and protein expression in cultured human osteoblasts. The involved signal pathway was studied using mitogen-activated protein kinase (MAPK) inhibitor and adiponectin receptor 1 (AdipoR1) siRNA. The effects of recombinant adiponectin on osteoclasts formation also were examined in the co-culture systems of osteoblast and peripheral blood monocytes (PBMCs) systems or purified CD14 + PBMCs cultures. RESULTS:Our study showed that recombinant adiponectin induced RANKL and inhibited OPG mRNA expression in human osteoblasts in a dose- and time-dependent manner. Adiponectin also increased soluble RANKL and decreased OPG secretion in osteoblasts conditioned media. Suppression of AdipoR1 with siRNA abolished the adiponectin-regulated RANKL and OPG mRNA expression in osteoblasts. Furthermore, pretreatment of osteoblasts with the MAPK inhibitor SB203580 abolished adiponectin-regulated RANKL and OPG mRNA expression. Adiponectin induced osteoclast formation in the co-culture systems of osteoblast and PBMCs systems, and OPG entirely blocked this response. However, adiponectin had no direct effect on the differentiation of osteoclast precursor purified CD14 + PBMCs. CONCLUSIONS:These data indicate that recombinant adiponectin induced RANKL and inhibited OPG expression in human osteoblasts through the AdipoR1/p38 MAPK pathway, and these responses contributed to the adiponectin-induced osteoclast formation in the co-culture of osteoblast and PBMCs systems. These findings showed that adiponectin increased osteoclast formation indirectly through stimulating RANKL and inhibiting OPG production in osteoblasts. It suggests the pharmacological nature of recombinant adiponectin that indirectly induces osteoclasts formation.

Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.

Adiponectin regulates the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand in human osteoblast

[Adiponectin Regulates the Expression of Osteoprotegerin and Receptor Activator of Nuclear Factor-Kappab Ligand in Human Osteoblast].

Effect of adiponectin on the expression of osteoprotegerin and receptor activator of nuclear factor-kappa B ligand in osteoblasts

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Adiponectin Stimulates Human Osteoblasts Proliferation and Differentiation Via the Mapk Signaling Pathway

Signal pathway involved in the effects of adiponectin on OPG and RANKL expressions in human osteoblasts

Effect of adiponectin on the expression of nuclear factor kappa B ligand receptor activator in human osteoblasts

[Effect of Adiponectin on Human Osteoblast Differentiation].

Adiponectin Exerts Its Negative Effect on Bone Metabolism Via OPG/RANKL Pathway: an in Vivo Study.

Effects of Adiponectin on Osteoclastogenesis from Mouse Bone Marrow-Derived Monocytes

Adiponectin stimulates human osteoblasts differentiation via the MAPK signaling pathway

Adiponectin Inhibits Osteoclastogenesis by Suppressing NF-κB and P38 Signaling Pathways.

Effects of 17Β-Estradiol on Adiponectin Regulation of the Expression of Osteoprotegerin and Receptor Activator of Nuclear Factor-Κb Ligand

Adipocytes Enhance Expression of Osteoclast Adhesion-Related Molecules Through the Cxcl12/Cxcr4 Signalling Pathway

Adiponectin Deficiency Triggers Bone Loss by Up-Regulation of Osteoclastogenesis and Down-Regulation of Osteoblastogenesis

Primary human bone marrow adipocytes support TNF-α-induced osteoclast differentiation and function through RANKL expression

Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways

Osteoprotegerin Influences The Bone Resorption Activity Of Osteoclasts

Adipocytes Decrease Runx2 Expression in Osteoblastic Cells: Roles of PPARγ and Adiponectin

Effects of Recombinant Human Osteoprotegerin and Recombinant RANK Protein on the Differentiation of Osteoclast Precursors